Beam Therapeutics (BEAM) News and press releases

Where Beam Therapeutics Stands With Analysts

21 Mar 23

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023

21 Mar 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Bernstein Initiates Coverage On Beam Therapeutics with Market Perform Rating, Announces Price Target of $37

21 Mar 23

News, Price Target, Initiation, Analyst Ratings

Bernstein analyst William Pickering initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Market Perform rating and announces Price Target of $37.

Looking Into Beam Therapeutics's Return On Capital Employed

6 Mar 23

Earnings

Where Beam Therapeutics Stands With Analysts

1 Mar 23

Analyst Ratings

Wells Fargo Maintains Overweight on Beam Therapeutics, Lowers Price Target to $105

1 Mar 23

News, Price Target, Analyst Ratings

Wells Fargo analyst Yanan Zhu maintains Beam Therapeutics (NASDAQ:BEAM) with a Overweight and lowers the price target from $125 to $105.

Beam Therapeutics Expects Cash, Cash Equivalents, And Marketable Securities Of $1.1B Will Enable The Company To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements At Least Into 2025

28 Feb 23

Biotech, Earnings, News, Health Care, General

This expectation includes funding directed toward reaching each of the key milestones for BEAM-101, BEAM-201, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and

Beam Therapeutics Q4 EPS $(0.54) Beats $(1.33) Estimate, Sales $20.04M Beat $12.53M Estimate

28 Feb 23

Earnings, News

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(1.33) by 59.4 percent. This is a 43.16 percent increase over losses of $(0.95) per share from

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023

1 Feb 23

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Analyst Ratings for Beam Therapeutics

1 Feb 23

Analyst Ratings

Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62

1 Feb 23

News, Price Target, Initiation, Analyst Ratings

Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $62.

SVB Leerink Maintains Outperform on Beam Therapeutics, Lowers Price Target to $77

23 Jan 23

News, Price Target, Analyst Ratings

SVB Leerink analyst Mani Foroohar maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and lowers the price target from $81 to $77.

Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones

9 Jan 23

News

BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with

Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away'

4 Jan 23

Biotech, News, Broad U.S. Equity ETFs, Small Cap, Markets, ETFs, General

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

21 Mar 23

News, Management, Press Releases

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Gopi Shanker, Ph.D.,

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

15 Mar 23

Health Care, Press Releases

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella,

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

1 Mar 23

News, Health Care, Press Releases

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

28 Feb 23

Earnings, Press Releases

Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expanding Investment in a Broad Portfolio of Potential New Programs Designed to Extend Reach of Base Editing Medicines

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

7 Feb 23

News, Press Releases

CAMBRIDGE, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

9 Jan 23

Press Releases

BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in Patients with T-ALL/T-LL

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

3 Jan 23

News, Press Releases

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will